Evaluation of The MD Anderson Tumor Score for Diffuse Large B-cell Lymphoma in the Rituximab Era.
DLBCL is an aggressive heterogeneous lymphoma with standard treatment. However, 30-40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot identify a very high risk (HR) subset. The MD Anderson Cancer Center reported a score in the pre-rituximab era exclusively considering tumor-related variables: Tumor Score (TS). We aim to validate TS in the rituximab era and to analyze its current potential role. From GELTAMO DLBCL registry we selected those patients homogeneously treated with R-CHOP (n=1327). 5y-PFS and OS were 62% and 74%. All variables retained an independent prognostic role in the revised TS (R-TS), identifying four different risk groups, with 5y-PFS of 86%, 71%, 50% and very HR (28%). With a further categorization of 3 variables of the original TS (Ann Arbor Stage, LDH and B2M) we generated a new index that allowed an improvement in HR assessment. 1) All variables of the original TS retain an independent prognostic role and R-TS remains predictive in the rituximab era; 2) R-TS and additional categorization of LDH, B2M and AA stage (enhanced-TS) increased the ability to identify HR subsets.